Analyst Price Targets — HAE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 15, 2026 10:38 am | Anthony Petrone | Mizuho Securities | $85.00 | $78.20 | StreetInsider | Haemonetics (HAE) PT Raised to $85 at Mizuho |
| May 12, 2026 11:37 am | — | Barrington | $89.00 | $52.24 | TheFly | Haemonetics price target lowered to $89 from $94 at Barrington |
| May 8, 2026 12:48 pm | David Rescott | Robert W. Baird | $67.00 | $51.55 | TheFly | Haemonetics price target lowered to $67 from $72 at Baird |
| April 13, 2026 2:40 pm | Anthony Petrone | Mizuho Securities | $70.00 | $57.39 | TheFly | Haemonetics price target lowered to $70 from $80 at Mizuho |
| February 6, 2026 2:45 pm | — | Robert W. Baird | $81.00 | $61.40 | TheFly | Haemonetics price target lowered to $81 from $99 at Baird |
| February 6, 2026 12:37 pm | — | Barrington | $94.00 | $65.02 | TheFly | Haemonetics price target raised to $94 from $93 at Barrington |
| February 6, 2026 12:36 pm | — | Mizuho Securities | $80.00 | $65.02 | TheFly | Haemonetics price target lowered to $80 from $90 at Mizuho |
| January 12, 2026 12:37 pm | — | Barrington | $93.00 | $82.03 | TheFly | Haemonetics price target raised to $93 from $90 at Barrington |
| December 17, 2025 11:57 am | — | Mizuho Securities | $90.00 | $81.11 | TheFly | Haemonetics price target raised to $90 from $75 at Mizuho |
| December 15, 2025 2:16 pm | — | Robert W. Baird | $99.00 | $80.33 | TheFly | Haemonetics price target raised to $99 from $87 at Baird |
Latest News for HAE
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
On June 25, 2026, Haemonetics Corp (HAE) shares rose 6.5% today, bringing the current price to $77.62. The stock has experienced a 52-week range between $47.32
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026…
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HAE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.